Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 117Triple Negative Breast Neoplasms 27Neoplasm Metastasis 18Sarcoma 17Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Brain Neoplasms 5Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Transitional Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leiomyosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Breast Cancer 2

Interventions

eribulin 1Vinorelbine 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HR+HER2- Breast Cancer × eribulin × Clear all
NCT06343948 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
383 enrolled
Breast

HR+HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡